Slow-release insulin in cystic fibrosis patients with glucose intolerance: A randomized clinical trial

Pediatric Diabetes

Volumn 13, Issue 2, 2012, Pages 197-202

  Minicucci, Laura ^a   Haupt, Maria ^a   Casciaro, Rosaria ^a   De Alessandri, Alessandra ^a   Bagnasco, Francesca ^a   Lucidi, Vincenzina ^b   Notarnicola, Sara ^a   Lorini, Renata ^a   Bertasi, Serenella ^c   Raia, Valeria ^d   Cialdella, Pietro ^c   Haupt, Riccardo ^a  

^a G GASLINI INSTITUTE   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c CF Center   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cystic fibrosis; Glargine; Glucose intolerance

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE;

ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG RELEASE; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; MALE; MORNING DOSAGE; MULTICENTER STUDY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ADULT; BODY MASS INDEX; CHILD; CYSTIC FIBROSIS; FEMALE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; LUNG; MALE; MIDDLE AGED; PATIENT COMPLIANCE; YOUNG ADULT;

EID: 84857500402     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2011.00810.x     Document Type: Article

References (22)

1. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992: 151: 684-687.
2. Sims EJ, Green MW, Metha A. Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. Diabetes Care 2005: 28: 1581-1587.
3. Chamnan P, Shine SF, Haworth C, Bilton D, Adler A. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010: 33: 311-316.
4. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2010: 33: 1626-1631.
5. Brennan A, Gyi K, Wood D, Johnson J. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007: 6: 101-109.
6. Hameed S, Morton J, Jaffe A et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010: 33: 221-226.
7. Milla C, Warwick W, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000: 162: 891-895.
8. Rolon MA, Benali K, Munck A et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001: 90: 860-867.
9. Lanng S, Thorsteinsson B, Nerup J, Kock C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992: 151: 684-687.
10. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr 2001: 90: 515-519.
11. Dobson L, Hatterssley A, Tiley S, Elworthy S, Oades P, Sheldon C. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child 2002: 87: 430-431.
12. Report of the UK Cystic Fibrosis Trust Diabetes Working Group. Management of cystic fibrosis related diabetes mellitus. Bromley, Kent: Cystic fibrosis trust, 2004.
13. Tofe S, Moreno JC, Maiz L, Alonso M, Escobar H, Barrio R. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur J Endocrinol 2005: 152: 241-247.
14. O'Riordan S, Dattari M, Hindmarrsh P. Cystic fibrosis-related diabetes in childhood. Hormone research in paediatrics. Horm Res Paediatr 2010: 73: 15-24.
15. Moran A, Pekow P, Grover P et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia. Diabetes Care 2010: 32: 1783-1788.
16. Moran A. Abnormal glucose tolerance in CF-When should we offer diabetes treatment? Pediatr Diabetes 2009: 10: 159-161.
17. O'Riordan S, Robinson P, Donaghue K, Moran A. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatric Diabetes 2009: 10 (Suppl. 12): 43-50.
18. Moran A, Brunzel C, Cohen RC et al. Clinical Care Guidelines for cystic fibrosis-related diabetes. Diabetes Care 2010: 33: 2697-2708.
19. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990: 44: 45-60.
20. Rolland-Cacherà MF, Cole TJ, Sempè Tichet J, Rossignol C, Charraud A. Body mass index variations: centiles from birth to 87 years. Eur J Clin Nutr 1991: 45: 13-21.
21. Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006: 29: 1-4.
22. Mozzillo E, Franzese A, Valerio G et al. One-year glargine treatment can improve the course of lung disease in chlidren and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes 2009: 10: 162-167.